{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:39:17Z","timestamp":1791639557344,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20fk0108102"],"award-info":[{"award-number":["JP20fk0108102"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20fk0210040"],"award-info":[{"award-number":["JP20fk0210040"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology, Japan","doi-asserted-by":"crossref","award":["JP18H02661"],"award-info":[{"award-number":["JP18H02661"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The global incidence of dengue, which is caused by dengue virus (DENV) infection, has grown dramatically in recent decades and secondary infection with heterologous serotype of the virus may cause severe symptoms. Efficacious dengue vaccines should be able to provide long-lasting immunity against all four DENV serotypes simultaneously. In this study, we constructed a novel vaccine platform based on tetravalent dengue virus-like particles (DENV-LPs) in which envelope (E) protein carried a FLAG tag sequence at the position located not only in the exterior loop on the protruding domain but outside of dimerization interface of the protein. We demonstrated an effective strategy to produce the DENV-LPs by transient transfection with expression plasmids for pre-membrane and E proteins of DENV-1 to DENV-4 in mammalian cells and to concentrate and purify them with one-step affinity chromatography. Characteristic features of VLPs such as particle size, shape and density were comparable to flavivirus-like particles reported. The neutralizing activity against all four DENV serotypes was successfully induced by immunization with the purified tetravalent VLPs in mice. Simple, one-step purification systems for VLP vaccine platforms using epitope-tagging strategy should be advantageous for vaccine development not only for dengue but for emerging pandemics in the future.<\/jats:p>","DOI":"10.1038\/s41598-021-97038-4","type":"journal-article","created":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T14:32:14Z","timestamp":1632407534000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Virus-like particles with FLAG-tagged envelope protein as a tetravalent dengue vaccine candidate"],"prefix":"10.1038","volume":"11","author":[{"given":"Toshifumi","family":"Imagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mami","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhei","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Cheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,2]]},"reference":[{"key":"97038_CR1","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nature12060","volume":"496","author":"S Bhatt","year":"2013","unstructured":"Bhatt, S. et al. The global distribution and burden of dengue. Nature 496, 504\u2013507 (2013).","journal-title":"Nature"},{"key":"97038_CR2","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s41564-019-0376-y","volume":"4","author":"MUG Kraemer","year":"2019","unstructured":"Kraemer, M. U. G. et al. Past and future spread of the arbovirus vectors Aedes aegypti and Aedes albopictus. Nat. Microbiol. 4, 854\u2013863 (2019).","journal-title":"Nat. Microbiol."},{"key":"97038_CR3","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3390\/v12080829","volume":"12","author":"H Harapan","year":"2020","unstructured":"Harapan, H., Michie, A., Sasmono, R. T. & Imrie, A. Dengue: A minireview. Viruses 12, 829 (2020).","journal-title":"Viruses"},{"key":"97038_CR4","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S0140-6736(14)60572-9","volume":"385","author":"MG Guzman","year":"2015","unstructured":"Guzman, M. G. & Harris, E. Dengue. Lancet 385, 453\u2013465 (2015).","journal-title":"Lancet"},{"key":"97038_CR5","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1126\/science.aan6836","volume":"358","author":"LC Katzelnick","year":"2017","unstructured":"Katzelnick, L. C. et al. Antibody-dependent enhancement of severe dengue disease in humans. Science 358, 929\u2013932 (2017).","journal-title":"Science"},{"key":"97038_CR6","doi-asserted-by":"publisher","first-page":"4338","DOI":"10.1128\/JVI.02574-08","volume":"83","author":"V Nayak","year":"2009","unstructured":"Nayak, V. et al. Crystal structure of dengue virus type 1 envelope protein in the postfusion conformation and its implications for membrane fusion. J. Virol. 83, 4338\u20134344 (2009).","journal-title":"J. Virol."},{"key":"97038_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nature14130","volume":"520","author":"A Rouvinski","year":"2015","unstructured":"Rouvinski, A. et al. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature 520, 109\u2013113 (2015).","journal-title":"Nature"},{"key":"97038_CR8","unstructured":"World Health Organization. Global strategy for dengue prevention and control 2012\u20132020. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/75303\/9789241504034_eng.pdf?sequence=1&isAllowed=y (2012)."},{"key":"97038_CR9","unstructured":"Strategic Advisory Group of Experts Working Group on Dengue Vaccines. Background paper on dengue vacines. http:\/\/www.who.int\/immunization\/sage\/meetings\/2016\/april\/1_Background_Paper_Dengue_Vaccines_2016_03_17.pdf (2016)."},{"key":"97038_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1056\/NEJMoa1800820","volume":"379","author":"S Sridhar","year":"2018","unstructured":"Sridhar, S. et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N. Engl. J. Med. 379, 327\u2013340 (2018).","journal-title":"N. Engl. J. Med."},{"key":"97038_CR11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/1743-422X-8-333","volume":"8","author":"S Zhang","year":"2011","unstructured":"Zhang, S. et al. Vaccination with dengue virus-like particles induces humoral and cellular immune responses in mice. Virol. J. 8, 333 (2011).","journal-title":"Virol. J."},{"key":"97038_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/JVI.01181-17","volume":"91","author":"A Urakami","year":"2017","unstructured":"Urakami, A. et al. An envelope-modified tetravalent dengue virus-like-particle vaccine has implications for flavivirus vaccine design. J. Virol. 91, 1\u201316 (2017).","journal-title":"J. Virol."},{"key":"97038_CR13","first-page":"1986","volume":"125","author":"Y-X Tang","year":"2012","unstructured":"Tang, Y.-X. et al. Induction of virus-neutralizing antibodies and T cell responses by dengue virus type 1 virus-like particles prepared from Pichia pastoris. Chin. Med. J. (Engl) 125, 1986\u20131992 (2012).","journal-title":"Chin. Med. J. (Engl)"},{"key":"97038_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-26904-5","volume":"8","author":"RK Rajpoot","year":"2018","unstructured":"Rajpoot, R. K., Shukla, R., Arora, U., Swaminathan, S. & Khanna, N. Dengue envelope-based \u2018four-in-one\u2019 virus-like particles produced using Pichia pastoris induce enhancement-lacking, domain III-directed tetravalent neutralising antibodies in mice. Sci. Rep. 8, 1\u201314 (2018).","journal-title":"Sci. Rep."},{"key":"97038_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0006191","volume":"12","author":"V Ramasamy","year":"2018","unstructured":"Ramasamy, V. et al. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice. PLoS Negl. Trop. Dis. 12, 1\u201326 (2018).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"97038_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1477-3155-10-30","volume":"10","author":"U Arora","year":"2012","unstructured":"Arora, U., Tyagi, P., Swaminathan, S. & Khanna, N. Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2. J. Nanobiotechnology 10, 30 (2012).","journal-title":"J. Nanobiotechnology"},{"key":"97038_CR17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13568-020-01087-3","volume":"10","author":"DIS Utomo","year":"2020","unstructured":"Utomo, D. I. S., Pambudi, S., Sjatha, F., Kato, T. & Park, E. Y. Production of dengue virus-like particles serotype-3 in silkworm larvae and their ability to elicit a humoral immune response in mice. AMB Express 10, 147 (2020).","journal-title":"AMB Express"},{"key":"97038_CR18","doi-asserted-by":"publisher","first-page":"28688","DOI":"10.1038\/srep28688","volume":"6","author":"R Saga","year":"2016","unstructured":"Saga, R. et al. Bivalent vaccine platform based on Japanese encephalitis virus (JEV) elicits neutralizing antibodies against JEV and hepatitis C virus. Sci. Rep. 6, 28688 (2016).","journal-title":"Sci. Rep."},{"key":"97038_CR19","doi-asserted-by":"publisher","first-page":"7769","DOI":"10.1128\/JVI.75.16.7769-7773.2001","volume":"75","author":"WD Crill","year":"2001","unstructured":"Crill, W. D. & Roehrig, J. T. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to vero cells. J. Virol. 75, 7769\u20137773 (2001).","journal-title":"J. Virol."},{"key":"97038_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/0042-6822(65)90147-9","volume":"27","author":"TM Stevens","year":"1965","unstructured":"Stevens, T. M. & Schlesinger, R. W. Studies on the nature of dengue viruses. I. Correlation of particle density, infectivity, and RNA content of type 2 virus. Virology 27, 103\u2013112 (1965).","journal-title":"Virology"},{"key":"97038_CR21","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1128\/jvi.5.4.524-532.1970","volume":"5","author":"TJ Smith","year":"1970","unstructured":"Smith, T. J., Brandt, W. E., Swanson, J. L., McCown, J. M. & Buescher, E. L. Physical and biological properties of dengue-2 virus and associated antigens. J. Virol. 5, 524\u2013532 (1970).","journal-title":"J. Virol."},{"key":"97038_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12985-018-0970-2","volume":"15","author":"SW Metz","year":"2018","unstructured":"Metz, S. W. et al. Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope. Virol. J. 15, 1\u201310 (2018).","journal-title":"Virol. J."},{"key":"97038_CR23","doi-asserted-by":"publisher","first-page":"e00286","DOI":"10.1016\/j.heliyon.2017.e00286","volume":"3","author":"S Matsuda","year":"2017","unstructured":"Matsuda, S. et al. Development of a Japanese encephalitis virus-like particle vaccine in silkworms using codon-optimised prM and envelope genes. Heliyon 3, e00286 (2017).","journal-title":"Heliyon"},{"key":"97038_CR24","doi-asserted-by":"publisher","first-page":"7728","DOI":"10.1016\/j.vaccine.2018.10.072","volume":"36","author":"H Boigard","year":"2018","unstructured":"Boigard, H., Cimica, V. & Galarza, J. M. Dengue-2 virus-like particle (VLP) based vaccine elicits the highest titers of neutralizing antibodies when produced at reduced temperature. Vaccine 36, 7728\u20137736 (2018).","journal-title":"Vaccine"},{"key":"97038_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmicb.2017.02644","volume":"8","author":"R Shukla","year":"2018","unstructured":"Shukla, R. et al. Pichia pastoris-expressed bivalent virus-like particulate vaccine induces domain III-focused bivalent neutralizing antibodies without antibody-dependent enhancement in vivo. Front. Microbiol. 8, 1\u201316 (2018).","journal-title":"Front. Microbiol."},{"key":"97038_CR26","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00705-012-1565-7","volume":"158","author":"L Huhti","year":"2013","unstructured":"Huhti, L., Tamminen, K., Vesikari, T. & Blazevic, V. Characterization and immunogenicity of norovirus capsid-derived virus-like particles purified by anion exchange chromatography. Arch. Virol. 158, 933\u2013942 (2013).","journal-title":"Arch. Virol."},{"key":"97038_CR27","doi-asserted-by":"publisher","first-page":"18662","DOI":"10.1073\/pnas.1310962110","volume":"110","author":"EA Christian","year":"2013","unstructured":"Christian, E. A. et al. Atomic-level functional model of dengue virus Envelope protein infectivity. Proc. Natl. Acad. Sci. USA 110, 18662\u201318667 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"97038_CR28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41598-017-18445-0","volume":"8","author":"M Matsuda","year":"2018","unstructured":"Matsuda, M. et al. High-throughput neutralization assay for multiple flaviviruses based on single-round infectious particles using dengue virus type 1 reporter replicon. Sci. Rep. 8, 4\u20137 (2018).","journal-title":"Sci. Rep."},{"key":"97038_CR29","doi-asserted-by":"publisher","first-page":"W296","DOI":"10.1093\/nar\/gky427","volume":"46","author":"A Waterhouse","year":"2018","unstructured":"Waterhouse, A. et al. SWISS-MODEL: Homology modelling of protein structures and complexes. Nucleic Acids Res. 46, W296\u2013W303 (2018).","journal-title":"Nucleic Acids Res."},{"key":"97038_CR30","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF Chimera\u2014A visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605\u20131612 (2004).","journal-title":"J. Comput. Chem."},{"key":"97038_CR31","doi-asserted-by":"publisher","first-page":"21940","DOI":"10.1021\/acsomega.0c03269","volume":"5","author":"M Ogata","year":"2020","unstructured":"Ogata, M. et al. Agglutination of human polyomaviruses by using a tetravalent glycocluster as a cross-linker. ACS Omega 5, 21940\u201321947 (2020).","journal-title":"ACS Omega"},{"key":"97038_CR32","unstructured":"R Core Team. R: A language and environment for statistical computing, Vienna, Austria. https:\/\/www.R-project.org\/ (2019)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97038-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97038-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97038-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T15:29:12Z","timestamp":1670081352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97038-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,2]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["97038"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-97038-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,2]]},"assertion":[{"value":"4 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17542"}}